The Future of Drug Discovery

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. Provides an in-depth, broad perspective on the crisis in drug industry Exposes the disconnect between what society needs and what the drug companies are working on Analyses and projects over 10 years into the future Explains what it means for scientists and society Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat

Produk Detail:

  • Author : Tamas Bartfai
  • Publisher : Academic Press
  • Pages : 376 pages
  • ISBN : 0124095194
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKThe Future of Drug Discovery

The Future of Drug Discovery

The Future of Drug Discovery
  • Author : Tamas Bartfai,Graham V. Lees
  • Publisher : Academic Press
  • Release : 18 May 2013
GET THIS BOOKThe Future of Drug Discovery

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the

The Future of Pharmaceutical Product Development and Research

The Future of Pharmaceutical Product Development and Research
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 02 September 2020
GET THIS BOOKThe Future of Pharmaceutical Product Development and Research

The Future of Pharmaceutical Product Development and Research examines the latest developments in the pharmaceutical sciences, also highlighting key developments, research and future opportunities. Written by experts in the field, this volume in the Advances in Pharmaceutical Product Development and Research series deepens our understanding of the product development phase of drug discovery and drug development. Each chapter covers fundamental principles, advanced methodologies and technologies employed by pharmaceutical scientists, researchers and the pharmaceutical industry. The book focuses on excipients, radiopharmaceuticals,

The Future of Pharmaceutical Product Development and Research

The Future of Pharmaceutical Product Development and Research
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 19 August 2020
GET THIS BOOKThe Future of Pharmaceutical Product Development and Research

The Future of Pharmaceutical Product Development and Research examines the latest developments in the pharmaceutical sciences, also highlighting key developments, research and future opportunities. Written by experts in the field, this volume in the Advances in Pharmaceutical Product Development and Research series deepens our understanding of the product development phase of drug discovery and drug development. Each chapter covers fundamental principles, advanced methodologies and technologies employed by pharmaceutical scientists, researchers and the pharmaceutical industry. The book focuses on excipients, radiopharmaceuticals,

Challenges for the FDA

Challenges for the FDA
  • Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation
  • Publisher : National Academies Press
  • Release : 02 October 2007
GET THIS BOOKChallenges for the FDA

As the principal agency regulating food, drugs, medical devices, and biological products used by Americans, the U.S. Food and Drug Administration (FDA) serves one of the most critical consumer protection functions of the federal government. The FDA's reach is enormous, regulating products that represent roughly 25 percent of all consumer spending in the United States. Since 1992, however, federal funding for the agency has diminished, and the FDA's Center for Drug Evaluation and Research (CDER) currently relies on the fees it

Phenotypic Drug Discovery

Phenotypic Drug Discovery
  • Author : Beverley Isherwood,Angelique Augustin
  • Publisher : Royal Society of Chemistry
  • Release : 10 December 2020
GET THIS BOOKPhenotypic Drug Discovery

Phenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of new medical entities. How many marketed drugs are derived from phenotypic screens? From the most recent examples, what were the factors enabling target identification and validation? This book answers these questions by elaborating on fundamental capabilities required for phenotypic drug discovery and using case studies to illustrate approaches and key success factors. Written and edited by experienced practitioners from both industry and

Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic

Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic
  • Author : Peggy L. Carver
  • Publisher : Walter de Gruyter GmbH & Co KG
  • Release : 14 January 2019
GET THIS BOOKEssential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic

Volume 19, entitled Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic of the series Metal Ions in Life Sciences centers on the role of metal ions in clinical medicine. Metal ions are tightly regulated in human health: while essential to life, they can be toxic as well. Following an introductory chapter briefly discussing several important metal-related drugs and diseases and a chapter about drug development, the focus is fi rst on iron: its essentiality for

Translational Medicine

Translational Medicine
  • Author : James Mittra,Christopher-Paul Milne
  • Publisher : CRC Press
  • Release : 19 April 2016
GET THIS BOOKTranslational Medicine

This book brings together a range of academic, industry and practitioner perspectives on translational medicine (TM). It enhances conceptual and practical understanding of the emergence and progress of the field and its potential impact on basic research, therapeutic development, and institutional infrastructure. In recognition of the various implications TM has for public health policy and commercial innovation, the book addresses the major systemic aspects of the field. The contributors explore the dynamic interactions and key challenges in translating new science

Challenges for the FDA

Challenges for the FDA
  • Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation
  • Publisher : National Academies Press
  • Release : 02 November 2007
GET THIS BOOKChallenges for the FDA

As the principal agency regulating food, drugs, medical devices, and biological products used by Americans, the U.S. Food and Drug Administration (FDA) serves one of the most critical consumer protection functions of the federal government. The FDA's reach is enormous, regulating products that represent roughly 25 percent of all consumer spending in the United States. Since 1992, however, federal funding for the agency has diminished, and the FDA's Center for Drug Evaluation and Research (CDER) currently relies on the fees it

Artificial Intelligence in Drug Discovery

Artificial Intelligence in Drug Discovery
  • Author : Nathan Brown
  • Publisher : Royal Society of Chemistry
  • Release : 11 November 2020
GET THIS BOOKArtificial Intelligence in Drug Discovery

Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and

Drug Repositioning: Current Advances and Future Perspectives

Drug Repositioning: Current Advances and Future Perspectives
  • Author : Yuhei Nishimura,Hideaki Hara
  • Publisher : Frontiers Media SA
  • Release : 11 January 2019
GET THIS BOOKDrug Repositioning: Current Advances and Future Perspectives

Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically,

Integration of Pharmaceutical Discovery and Development

Integration of Pharmaceutical Discovery and Development
  • Author : Ronald T. Borchardt,Roger M. Freidinger,Tomi K. Sawyer,Philip L. Smith
  • Publisher : Springer Science & Business Media
  • Release : 11 April 2006
GET THIS BOOKIntegration of Pharmaceutical Discovery and Development

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high

Social Aspects of Drug Discovery, Development and Commercialization

Social Aspects of Drug Discovery, Development and Commercialization
  • Author : Odilia Osakwe,Syed A.A. Rizvi
  • Publisher : Academic Press
  • Release : 18 February 2016
GET THIS BOOKSocial Aspects of Drug Discovery, Development and Commercialization

Social Aspects of Drug Discovery, Development and Commercialization provides an insightful analysis of the drug discovery and development landscape as it relates to society. This book examines the scientific, legal, philosophical, economic, political, ethical and cultural factors that contribute to drug development. The pharmaceutical industry is under scrutiny to develop safer and more effective drugs in a quicker and more affordable manner. Recent criticism and debates have emphasized varying opinions on the issues concerning the drug discovery and development process.

Basic Principles of Drug Discovery and Development

Basic Principles of Drug Discovery and Development
  • Author : Benjamin E. Blass
  • Publisher : Academic Press
  • Release : 25 May 2021
GET THIS BOOKBasic Principles of Drug Discovery and Development

Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics. Given the wide range of disciplines and

The Future of Drug Safety

The Future of Drug Safety
  • Author : Institute of Medicine,Board on Population Health and Public Health Practice,Committee on the Assessment of the US Drug Safety System
  • Publisher : National Academies Press
  • Release : 27 February 2007
GET THIS BOOKThe Future of Drug Safety

In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to